Qsemble Capital Management LP Purchases 36,811 Shares of DexCom, Inc. (NASDAQ:DXCM)

Qsemble Capital Management LP grew its position in DexCom, Inc. (NASDAQ:DXCM) by 793.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,449 shares of the medical device company’s stock after purchasing an additional 36,811 shares during the period. Qsemble Capital Management LP’s holdings in DexCom were worth $2,779,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Whetstone Capital Advisors LLC grew its stake in DexCom by 538.6% in the third quarter. Whetstone Capital Advisors LLC now owns 70,065 shares of the medical device company’s stock valued at $4,697,000 after acquiring an additional 59,093 shares during the period. Blue Whale Capital LLP lifted its stake in shares of DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after buying an additional 113,000 shares during the last quarter. Harvest Fund Management Co. Ltd grew its holdings in DexCom by 53.4% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 18,459 shares of the medical device company’s stock valued at $1,237,000 after buying an additional 6,425 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of DexCom during the third quarter worth approximately $961,000. Finally, Fisher Asset Management LLC raised its stake in DexCom by 10.6% in the third quarter. Fisher Asset Management LLC now owns 856,124 shares of the medical device company’s stock valued at $57,395,000 after purchasing an additional 82,250 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,431 shares of company stock worth $399,319. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Performance

DXCM opened at $77.83 on Tuesday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market cap of $30.40 billion, a P/E ratio of 46.60, a price-to-earnings-growth ratio of 2.23 and a beta of 1.17. The firm’s 50-day moving average price is $70.76 and its 200-day moving average price is $88.93.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DXCM shares. Robert W. Baird raised their price objective on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. Oppenheimer lowered their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Barclays cut their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. Finally, Sanford C. Bernstein increased their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.